Skip to content
OpenCapital
Get started

Immix Biopharma, Inc. IMMX Q1 2026 earnings

Reported May 7, 2026

EPS-$0.18Beat by $0.00
EPS estimate-$0.18

Next report

Aug 14, 2026 (In 2 weeks)
EPS estimate-$0.17

Financials

Q1 2026

Income statement

See full
Operating income-$10.8M-131%
Net income-$10.1M-122%
EPS (diluted)-$0.18-20.0%

Balance sheet

See full
Cash & equivalents$79.3M+398%
Total debt$1.0M-2.0%
Total equity$84.4M+779%
Total assets$95.8M+382%

Cash flow

See full
Operating cash flow-$9.8M-483%
CapEx$32.5K-52.0%
Free cash flow-$9.9M-462%

Valuation & ratios

Valuation

as of 07/28/26
See full
Market cap$618.64M+716%
Enterprise value$540.43M+728%

Returns & leverage

See full
Return on equity-74.4%-18.6pp
Debt / equity0×-0.1×
Current ratio8.8×+7.0×

Versus estimates

Revenue

Q4 2024$96.3K

Diluted EPS

Q1 2026-$0.18Beat by $0.00
Q3 2025-$0.24Miss by $0.05Q2 2025-$0.22Miss by $0.01Q1 2025-$0.15Beat by $0.08Q4 2024-$0.16Beat by $0.09Q3 2024-$0.24Miss by $0.08

Ask the moment Immix Biopharma, Inc. reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

When did Immix Biopharma, Inc. report Q1 2026 earnings?
Immix Biopharma, Inc. (IMMX) reported Q1 2026 earnings on May 7, 2026.
What were Immix Biopharma, Inc.'s Q1 2026 revenue and EPS?
Immix Biopharma, Inc. reported eps of $-0.18 for Q1 2026.
Did Immix Biopharma, Inc. beat estimates in Q1 2026?
EPS beat the consensus estimate of $-0.18 by $0.00.
How did Immix Biopharma, Inc.'s Q1 2026 results compare year-over-year?
Compared to the same quarter a year prior, eps declined 20.0% from $-0.15.
Where can I find Immix Biopharma, Inc.'s Q1 2026 SEC filings?
You can read the 10-Q periodic report (0001493152-26-021764) directly on SEC EDGAR. The filing index links above go to sec.gov.